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erelin (G) and triptorelin (T) for Russian health care system. METHODS: A review
was conducted to collect available evidence of the clinical efficacy and safety of L in
comparison with G and T. Cost-minimization analysis was performed. Direct costs
of treatment with studied drugs were considered for each option: cost for 1- year
hormonal therapy in a hypothetical cohort of 100 patients with PC. The calculation
of costs was based on drugs’ pries from the List of Vital and Essential Drugs in
Moscow region. In addition we made an estimate of the number of extra patients
who could have been treated if a less expensive alternative had been applied.
One-way sensitivity analysis was made. RESULTS: According to available pub-
lished data LHRH agonists have similar clinical efficacy and safety that allowed us
to use cost-minimization method. Costs for the medications in a hypothetical co-
hort of 100 patients with PC were equal to 290.263; 332.690 and 391.595 USD per year
for L, G and T respectively. When L is used instead of G and T extra 14 and 34
patients can be treated with LHRH for 1 year respectively. Sensitivity analysis has
shown, that L is less expensive if its price is no more than 14,6 % and 34,91%
from baseline when compared to G and T respectively. CONCLUSIONS: L-based
therapy has equal clinical efficacy comparing to the other LHRH analogues and is
on average a cost saving option when compared with G and T.
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OBJECTIVES: This study analyzed the cost-utility of everolimus  exemestane
(EVEEXE) versus placebo  exemestane (PBOEXE) in patients with HR
HER2–ABC. METHODS: The phase III BOLERO-2 study randomized 724 patients
with HR HER2–ABC and recurrence or progression during/after nonsteroidal aro-
matase inhibitor therapy to EVEEXE or PBOEXE. A survival partition model was
developed to compare treatment with EVEEXE versus PBOEXE (UK health care
perspective). The 18-month median follow-up data on progression-free survival
and mortality were obtained from BOLERO-2. Weibull functions were used to ex-
trapolate trial data beyond the follow-up period. Utilities from published sources
were combined with trial data to calculate quality-adjusted life years (QALYs) as-
sociated with health state. Background health state costs (ie, non-intervention
costs) were applied to calculate incremental costs. RESULTS:At 18 months’ follow-
up, ABC patients on EVEEXE gained 1.33 life years (LYs) and 0.76 QALYs versus
1.27 LYs and 0.65 QALYs with PBOEXE. Background health state and adverse
event (AE) costs were £9,944 with EVEEXE versus £12,924 with PBOEXE. Exclud-
ing drug acquisition costs, use of EVEEXE resulted in cost savings of £2,980. When
trial data were extrapolated to 5 years, EVEEXE led to a gain of 3.05 LYs and 1.46
QALYs versus 2.57 LYs and 1.16 QALYs with PBOEXE. Background health state and
AE costs were £30,094 with EVEEXE versus £29,560 with PBOEXE. The incremen-
tal (non-intervention) cost was £534 (due to longer survival). CONCLUSIONS: These
additional analyses from the BOLERO-2 study show that compared with PBOEXE,
patients receiving EVEEXE experienced longer PFS, which translated to health
gains in terms of both LYs and QALYs. EVEEXE was associated with savings in
non-intervention costs over the initial trial period and a modest increase in non-
intervention costs over the extrapolated 5-year time horizon.
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OBJECTIVES: To assess cost-utility in Belgium of once-per-cycle primary prophy-
laxis (PP) with pegfilgrastim vs. no prophylaxis and vs. PP with daily granulocyte-
colony stimulating factors (G-CSF) filgrastim or lenograstim (11-days per label or 6-
days per common clinical practice) for reducing febrile neutropenia (FN) incidence
in women with primary breast cancer receiving chemotherapy carrying a 20% or
higher overall risk of FN. METHODS: A decision-analytic model was constructed
from a health care-payer perspective. Costs were from official Belgian list prices
(April 2012) or literature and included drugs, drug administration, FN-hospitaliza-
tions and FN-related medical costs. Effectiveness inputs in terms of relative risk
reduction (RRR) for FN were based on the most recently published meta-analysis
(Cooper 2011). Survival and utility inputs were obtained from available data for
breast cancer patients in the US (Lyman 2009) and the UK (Whyte 2011). Outcomes
included number needed to treat to avoid an episode of FN (NNT), and incremental
cost effectiveness ratio (ICER) in terms of cost per quality-adjusted life-years
(QALY). A univariate sensitivity analysis evaluated the robustness of the model.
RESULTS: Pegfilgrastim demonstrated the lowest NNT (4.69). In terms of cost-util-
ity, pegfilgrastim was dominant vs. 11-day filgrastim or lenograstim and was con-
sidered cost-effective vs. no prophylaxis (€24,675/QALY) and 6-day filgrastim
(€18,265/QALY) or lenograstim (€12,782/QALY). In a scenario analysis reducing the
prices of daily G-CSFs by 30%, pegfilgrastim remained cost-effective at a willing-
ness to pay threshold of €30,000. The sensitivity analysis revealed that most sen-
sitive variables were effectiveness (RRR), incremental utility values (LYs and
QALYs) and cost of G-CSFs, and demonstrated the overall model to be robust.
CONCLUSIONS: In a Belgian setting, pegfilgrastim offered the most cost-effective
approach to primary prophylaxis of FN. In the cost-utility analysis pegfilgrastim
primary prophylaxis was dominant vs. 11-day G-CSF primary prophylaxis and
cost-effective vs. no prophylaxis and 6-day G-CSF primary prophylaxis.
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OBJECTIVES: Based on an exploratory biomarker analysis in the Phase 3 RCT
LYM3001 Study that evaluated bortezomib combined with rituximab against ritux-
imab, in a biomarker positive population of relapsed/refractory follicular lym-
phoma (RRFL) patients (Coiffier et al 2011, ASH), a cost-utility analysis was con-
ducted from the UK NHS perspective. METHODS: A lifelong Markov model with
monthly cycles was designed in MS Excel 2007. Three health states were defined:
progression free, progression and death. Patients received active treatment for the
first 5 weeks in the progression free state and best supportive care in progression.
Progression free survival (PFS) probabilities were extrapolated from the random-
ized controlled trial. In the PSMB1 P11A C/G heterozygote and low CD68 expression
subgroup of RRFL patients, the median PFS improved from 9.1 to 16.6 months
(p0.0001) with bortezomib/rituximab vs. rituximab alone. This subgroup was
identified using laboratory tests. The total cost included the cost of drugs, admin-
istration, biomarker analysis, follow up, best supportive care, end of life care and
adverse events per health state. Utilities were state dependent and disutilities were
applied for adverse events. General mortality, unit costs and utilities were obtained
from the literature. Annual discounting of 3.5% was applied on costs and health
effects. The result measured the incremental cost (£ 2011) per quality adjusted life
year (QALY) gained. RESULTS: The combination bortezomib/rituximab yielded 9.76
QALYs vs. 8.41 for rituximab alone in biomarker positive RRFL patients. The pro-
jected total costs were £ 56,362 and £37,701, respectively. The resulting incremental
cost effectiveness ratio (ICER) was £13,774/QALY gained. The probabilistic sensitiv-
ity analysis indicated that the cost-effectiveness probability exceeded 55% at
£20,000/QALY. CONCLUSIONS: In RRFL patients with positive biomarkers, PSMB1
P11A C/G heterozygote and low CD68 expression, bortezomib/rituximab was com-
pared against rituximab and generated an ICER below £20,000/QALY gained. This
analysis shows how personalized medicine may maximize cost-effectiveness.
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OBJECTIVES: Metastatic renal cell cancer (mRCC) is becoming an important part of
Serbian health care expenditure due to its increasing incidence, inadequate pre-
vention methods and expensive pharmaceutical options for disease control. Of all
available treatment options, only sunitinib is currently reimbursed in Serbia. This
study aims to assess the cost-effectiveness of everolimus in comparison to best
supportive care in mRCC patients who failed to respond to treatment with
sunitinib. METHODS: A Markov model was designed with respect to the Serbian
treatment protocols and a health care perspective was taken. Transitions between
health states were enabled by time-dependent probabilities extracted from pub-
lished Kaplan-Meier curves for progression-free (PFS) and overall survival (OS). The
cohorts were followed over 18 cycles, each cycle lasting 8 weeks, which covers the
life-time horizon of mRCC patients. An annual discount rate of 1.5% for health and
4% for costs was applied. One-way and probabilistic sensitivity analyses (PSA) were
performed to test the robustness and uncertainty around the base-case estimate.
RESULTS: The incremental cost-effectiveness ratio (ICER) for everolimus was esi-
mated at 64,028€/QALY. Sensitivity analysis identified the probabilities of OS and
PFS as the main drivers of the cost-effectiveness of everolimus. The cost of everoli-
mus and the utilities estimates were also of significant influence. PSA revealed a
wide 95% confidence interval around the base-case ICER estimate (36,147 - 186,053
€/QALY). Additionally, at a threshold of 14,400€/QALY (three times the GDP per
capita in Serbia) everolimus did not have probability of being cost-effective.
CONCLUSIONS: Base-case ICER was significantly higher than the commonly used,
GDP-based threshold, recommended by WHO, indicating that everolimus would
most likely be a cost-ineffective treatment in Serbian setting. However, prior to a
final decision on the acceptance/rejection of everolimus, reassessment of the
whole therapeutic group might be needed to constitute reasonable treatment strat-
egies within the mRCC field.
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OBJECTIVES: Examine the incremental costs of absenteeism and short-term dis-
ability associated with colorectal cancer (CRC). METHODS: The MarketScan Com-
mercial Claims and Encounters (CCAE) and Health and Productivity Management
(HPM) databases were used to identify patients age 18-64 diagnosed with CRC, with
first such date identified as the index date. Patients were also required to have
continuous insurance coverage and be included in the HPM database from 6
months prior through 12 months post index date. These cases were matched 1:1
without replacement based upon age, sex, and region of residence and controls
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